Related Experiment Video
Updated: Jun 5, 2026
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
STAT3 at the tumor-immune interface: mechanisms of immune escape and therapeutic opportunities
Xuanya Cheng1, Haoren Jing2,3, Mingqing Zhang1,2,3
1Tianjin University of Traditional Chinese Medicine, College of Traditional Chinese Medicine, Tianjin, China.
Abstract:
Immune escape remains a major barrier to durable cancer immunotherapy. Although checkpoint blockade has transformed cancer treatment, resistance commonly reflects broader tumor-intrinsic and microenvironmental programs that sustain immune dysfunction. At this interface, STAT3 emerges as a central organizing node. Beyond its canonical role in inflammatory and oncogenic signaling, STAT3 links tumor cell plasticity, immune suppression, and metabolic adaptation across the tumor ecosystem. In tumor cells, STAT3 promotes stemness, survival, checkpoint ligand expression, impaired antigen presentation, and immunosuppressive secretomes. In immune compartments, it drives regulatory T cell expansion, myeloid-derived suppressor cell accumulation, tumor-associated macrophage polarization, and dendritic cell dysfunction, thereby stabilizing an immune-resistant niche. STAT3 also reinforces immune escape through metabolic rewiring and multicellular feed-forward circuits. These features make STAT3 an attractive but challenging therapeutic target. Here, we discuss how STAT3 functions at the tumor-immune interface to coordinate immune escape and highlight therapeutic opportunities for targeting this axis in cancer.
Insights
Signal transducer and activator of transcription 3 (STAT3) drives cancer immune escape by coordinating tumor cell plasticity, immune suppression, and metabolic adaptation. Targeting STAT3 offers a promising strategy to overcome immunotherapy resistance.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Cancer immunotherapy, particularly checkpoint blockade, has revolutionized treatment but faces resistance.
- Resistance often stems from tumor-intrinsic and microenvironmental factors that promote immune dysfunction.
- Signal transducer and activator of transcription 3 (STAT3) is a key signaling pathway implicated in both cancer and immune responses.
Purpose of the Study:
- To elucidate the multifaceted role of STAT3 at the tumor-immune interface in coordinating cancer immune escape.
- To highlight the therapeutic potential of targeting STAT3 signaling for enhancing cancer immunotherapy efficacy.
Main Methods:
- Review and synthesis of existing literature on STAT3 signaling in cancer and immunology.
- Analysis of STAT3's functions in tumor cells and immune compartments.
- Examination of STAT3's role in metabolic adaptation and multicellular interactions within the tumor ecosystem.
Main Results:
- STAT3 promotes tumor cell stemness, survival, checkpoint ligand expression, and immunosuppressive secretomes.
- In immune cells, STAT3 drives regulatory T cell expansion, myeloid-derived suppressor cell accumulation, and macrophage/dendritic cell dysfunction.
- STAT3 reinforces immune escape through metabolic rewiring and complex feed-forward circuits.
Conclusions:
- STAT3 acts as a central node coordinating diverse mechanisms of immune escape in cancer.
- Targeting STAT3 presents a promising, albeit challenging, therapeutic avenue to overcome immunotherapy resistance and improve patient outcomes.
Related Concept Videos
01:27Tumor Immunotherapy
02:17The Tumor Microenvironment
02:17The Tumor Microenvironment
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...